Skip to Main Content

Current Research

Check out the studies at Yale that are currently recruiting!

Less than 8 years old

There are no current ongoing studies in this age range that are recruiting participants.

Age 8- 17 years

There are no current ongoing studies in this age range that are recruiting participants.

Adult age 18+

There are no current ongoing studies in this age range that are recruiting participants.

New Diagnosis

TOPPLE T1D

A multiple ascending dose trial investigating safety, tolerability and pharmacokinetics of NNC0361-0041 administered subcutaneously to patients with type 1 diabetes mellitus (HIC#2000029217)

Type 1 Diabetes TrialNet is currently recruiting adults diagnosed with type 1 diabetes in the past 48 months for a Phase I clinical study testing the safety of a new plasmid therapy (NNC0361-0041).

Ages: 18-45

More information: www.trialnet.org

Contact: Lori Carria at lori.carria@yale.edu


PROTECT

Sponsored by Provention Bio, The PROTECT Study is testing how well an investigational medicine, called teplizumab, works in children and adolescents with Type 1 diabetes (T1D). your child is 8–17 years old and has recently been diagnosed with T1D he or she may be able to take part. Other medical criteria must be met before you can join the study, which will be assessed by the study team.

Ages: 8-17

Contact: Michele Alguard michele.alguard@yale.edu



Prevention and Family

These studies target people with relatives with Type 1 Diabetes or people who have been identified as being at risk for Type 1 Diabetes.


The Natural History Study of the Development of Type 1 Diabetes: Pathway to Prevention FOR FAMILY MEMBERS ONLY

(HIC # 0608001761)

The goal of this study is to learn more about how type 1 diabetes develops in "at-risk" individuals and is the first step in determining eligibility for prevention trials.

Ages: If you are 1-45 years of age AND have a brother, sister, child or parent with type 1 diabetes OR you are 1-20 years of age AND have a cousin, aunt, uncle, niece, nephew, half-sibling or grandparent with type 1 diabetes.

More information: Natural History Study

Contact: Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu


HYDROXYCHLOROQUINE (HCQ) FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS (HIC# 2000023905)

TrialNet investigators are testing a medication, called Hydroxychloroquine, to see if this treatment will delay or prevent the onset of abnormal glucose tolerance and type 1 diabetes in family members identified to be at risk for the disease. Participants in this study are screened in the Natural History/Pathway to Prevention Study.

Ages: at least 3 years old

More information: www.trialnet.org

Contact: Lori Carria at lori.carria@yale.edu